3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Stomach Neoplasms
1
Psychological Well-Being
1
Prostatic Neoplasms
1
Postoperative Complications
1
Motor Activity
1
Lung Neoplasms
1
Leiomyoma
1
Hypotension
1
Gynecologic Surgical Procedures
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
27
Oxaliplatin
24
Paclitaxel
22
Fluorouracil
21
Carboplatin
18
Leucovorin
16
Cisplatin
16
Capecitabine
16
Radiotherapy
15
Nivolumab
12
Drug Therapy
12
Radiation
10
Trastuzumab
9
Surgical Procedures, Operative
8
Immunotherapy
8
Magnetic Resonance Spectroscopy
7
Esophagectomy
7
Blood Specimen Collection
7
Taxes
6
tislelizumab
5
durvalumab
5
Surveys and Questionnaires
5
Specimen Handling
5
Radiotherapy, Intensity-Modulated
5
Irinotecan
5
Immune Checkpoint Inhibitors
5
Docetaxel
5
Bevacizumab
5
Ramucirumab
4
Fluorodeoxyglucose F18
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Tea
×
1 year
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled